

## Special Issue

# Precision Oncology for Rare Skin Cancers

### Message from the Guest Editors

Skin cancers, including melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (CSCC), collectively represent the most prevalent malignancies worldwide. While melanoma and Merkel cell carcinoma (MCC) have high mortality rates, a smaller percentage of CSCC or BCC cases lead to metastases or death. Other rare skin cancers, including sebaceous carcinoma, adnexal carcinoma, extramammary Paget's disease, and cutaneous sarcomas, may also cause profound mortality or morbidity among affected patients. This Special Issue will describe the precision oncology approach to rare skin cancers, and welcomes studies that describe the molecular underpinnings of these cancers, novel therapeutics and approaches to managing these tumors.

---

### Guest Editors

Dr. Gino K. In

USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Dr. Aparna Nallagangula

College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA

---

### Deadline for manuscript submissions

closed (31 December 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/189260](https://mdpi.com/si/189260)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)